TITLE

Clinical Profile of Botulinum Toxin A in Patients with Chronic Headaches and Cervical Dystonia: A Prospective, Open-Label, Longitudinal Study Conducted in a Naturalistic Clinical Practice Setting

AUTHOR(S)
Dowson, Andrew J; Kilminster, Shaun G; Salt, Rebecca
PUB. DATE
June 2008
SOURCE
Drugs in R&D;2008, Vol. 9 Issue 3, p147
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND AND OBJECTIVES: Some evidence for the efficacy of botulinum toxin A as a preventive treatment for chronic primary headaches has been reported in randomized, controlled clinical studies. This study investigated the clinical profile of botulinum toxin A in a naturalistic clinical practice setting in a population of patients with cervical dystonia associated with chronic headache and a history of migraine. METHODS: This was a prospective, open-label, longitudinal study. Following a prospective run-in period, eligible patients were given three sets of botulinum toxin A injections at 8- to 12-week intervals over a 16- to 24-week period and were monitored for 3 months after the final injections. Efficacy was assessed in terms of headache-related disability (using the Migraine Disability Assessment [MIDAS] questionnaire), pain and emotional function (using the Short Pain Inventory [SPI]), quality of life (QOL, using the Short-Form-36 [SF-36] questionnaire) and patient-assessed headache frequency and severity, and medication use and its effectiveness. Safety was assessed as adverse events. The primary endpoint was the change in MIDAS score from baseline following treatment with botulinum toxin A. RESULTS: Twenty-four patients took part in the study and 17 (71%) completed the study. There were significant improvements in headache-related disability (MIDAS score), pain and emotional function (SPI), QOL (SF-36), headache frequency and medication use following treatment with botulinum toxin A (p < 0.05 for all endpoints). An efficacy response occurred within 8 weeks of treatment initiation and was maintained throughout the study duration. Botulinum toxin A was generally well tolerated. CONCLUSIONS: This study demonstrated that botulinum toxin A is an effective and well tolerated preventive treatment for chronic headache in patients with cervical dystonia and a history of migraine. These results warrant further investigation in a large, randomized, controlled study.
ACCESSION #
31939670

 

Related Articles

  • New acute treatments for headache. Rapoport, Alan M. // Neurological Sciences;Jun2010, Vol. 31, p129 

    Although we have several acute care medications for the treatment of migraine, we are always looking for new medications to treat our patients. Patients often say that their headaches are not under optimal control and would be happy to try another medication. Patients look for faster onset of...

  • OnabotulinumtoxinA (BOTOX®): A Guide to Its Use in Preventing Headaches in Adults with Chronic Migraine. Lyseng-Williamson, Katherine A.; Frampton, James E. // CNS Drugs;2012, Vol. 26 Issue 8, p717 

    Intramuscular onabotulinumtoxinA (onaBoNTA; BOTOX®) is indicated for headache prophylaxis in adults with chronic migraine. According to pooled results from two large trials, treatment with up to five cycles of ona-BoNTA (155-195 units/cycle) at 12-week intervals was effective in reducing...

  • ANTINOCICEPTIVE EFFECTS OF BOTULINUM TOXIN TYPE-A IN PAIN AND HEADACHES TREATMENT. Relja, Maja // Rad Hrvatske Akademije Znanosti i Umjetnosti. Medicinske Znanost;Jun2009, Vol. 501 Issue 33, p123 

    Since its development for clinical use in 1980s botulinum toxin, the most potent biological toxin known to man has become a useful drug in various field of medicine. It was initially used to treat neurological disorders characterized by excessive muscle contractions. Since many patients report...

  • Xeomin, una neurotoxina botulínica tipo A libre de proteínas complejantes. Terradas, S. // El Farmacéutico Hospitales;oct2012, Issue 199, p18 

    Xeomin® is a pharmaceutical presentation of highly purified botulinum neurotoxin type A. The absence of complexing proteins in this formulation apparently does not affect its physicochemical stability, nor the risk of spread outside the target muscles nor the postinjection response time....

  • Mehanizam djelovanja i terapija botulinum toksinom. Alajbegović, Azra; Alajbegović, Salem; HalimaResić // Medicinski Arhiv;2008, Vol. 62 Issue 1, p53 

    Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum as a complex of proteins containing the neurotoxin itself and other nontoxic proteins. Activation of the neurotoxin occurs upon proteolytic cleavage into the heavy and light chains. This di-chain moiety is essential for neurotoxin...

  • Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients. Godeiro-Junior, Clecio; Felício, Andre C.; de Carvalho Aguiar, Patrícia; Borges, Vanderci; Silva, Sonia M. A.; Ferraz, Henrique B. // Canadian Journal of Neurological Sciences;Mar2009, Vol. 36 Issue 2, p222 

    Background: Cervical dystonia (CD) may be classified according to the underlying cause into primary or secondary CD. Previous exposure to neuroleptics is one of the main causes of adult-onset secondary dystonia. There are few reports that characterize the clinical features of primary CD and...

  • Ask Dr Andrew.  // Woman's Day (Australia Edition);2/13/2006, Vol. 58 Issue 7, p64 

    The article presents information on Botox. Botulinum toxin is a neurotoxin initially used to treat strabismus, blepharospasm and cervical dystonia. Currently, it is used cosmetically, particularly to improve and relax frown lines. Risks associated with the procedure include headache, dry eyes...

  • Mehanizam djelovanja i terapija botulinum toksinom. Alajbegović, Azra; Alajbegović, Salem; HalimaResić // Medical Archives / Medicinski Arhiv;2008, p53 

    Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum as a complex of proteins containing the neurotoxin itself and other nontoxic proteins. Activation of the neurotoxin occurs upon proteolytic cleavage into the heavy and light chains. This di-chain moiety is essential for neurotoxin...

  • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Ã… resolution. Hanson, Michael A.; Stevens, Raymond C. // Nature Structural Biology;Aug2000, Vol. 7 Issue 8, p687 

    Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics